Clinical trial

The efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - A randomized, double-blind, placebo-controlled study

T. Wittmann, L. Paradowski, P. DucrottÉ, L. Bueno, M. C. Andro Delestrain

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aliment Pharmacol Ther 31, 615-624 SummaryBackground Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited. Aim To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort. Methods A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks. Results The full analysis set included 409 patients (71.4% female: mean age: 46.2 ± 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups. Conclusion Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS.

Original languageEnglish
Pages (from-to)615-624
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume31
Issue number6
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Irritable Bowel Syndrome
Abdominal Pain
Placebos
Clinical Trials
Visual Analog Scale
alverine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical trial : The efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - A randomized, double-blind, placebo-controlled study. / Wittmann, T.; Paradowski, L.; DucrottÉ, P.; Bueno, L.; Andro Delestrain, M. C.

In: Alimentary Pharmacology and Therapeutics, Vol. 31, No. 6, 03.2010, p. 615-624.

Research output: Contribution to journalArticle

@article{e93a6e45e7304b6e84ad218ae87776ec,
title = "Clinical trial: The efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - A randomized, double-blind, placebo-controlled study",
abstract = "Aliment Pharmacol Ther 31, 615-624 SummaryBackground Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited. Aim To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort. Methods A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks. Results The full analysis set included 409 patients (71.4{\%} female: mean age: 46.2 ± 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8{\%} vs. 34.3{\%}, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups. Conclusion Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS.",
author = "T. Wittmann and L. Paradowski and P. Ducrott{\'E} and L. Bueno and {Andro Delestrain}, {M. C.}",
year = "2010",
month = "3",
doi = "10.1111/j.1365-2036.2009.04216.x",
language = "English",
volume = "31",
pages = "615--624",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Clinical trial

T2 - The efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome - A randomized, double-blind, placebo-controlled study

AU - Wittmann, T.

AU - Paradowski, L.

AU - DucrottÉ, P.

AU - Bueno, L.

AU - Andro Delestrain, M. C.

PY - 2010/3

Y1 - 2010/3

N2 - Aliment Pharmacol Ther 31, 615-624 SummaryBackground Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited. Aim To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort. Methods A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks. Results The full analysis set included 409 patients (71.4% female: mean age: 46.2 ± 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups. Conclusion Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS.

AB - Aliment Pharmacol Ther 31, 615-624 SummaryBackground Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited. Aim To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort. Methods A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks. Results The full analysis set included 409 patients (71.4% female: mean age: 46.2 ± 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups. Conclusion Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS.

UR - http://www.scopus.com/inward/record.url?scp=76449112444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449112444&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.04216.x

DO - 10.1111/j.1365-2036.2009.04216.x

M3 - Article

VL - 31

SP - 615

EP - 624

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 6

ER -